Barinthus Biotherapeutics Plc ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.10 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.74Price as of 8 Sep 2026 Data confidenceNot applicable Market Cap $30.2M Enterprise Value −$29.1M Shares Outstanding 41.1M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Barinthus Biotherapeutics is undergoing a transformative strategic pivot. By deprioritizing its legacy infectious disease and oncology assets, the company has sharply reduced its cash burn and refocused on high-potential immunology, inflammation, and autoimmune indications. The centerpiece of this transformation is the proposed all-stock merger with Clywedog Therapeutics. This transaction, expected to close in mid-2026, will create a diversified clinical-stage company (trading under the ticker 'CLYD') targeting both celiac disease and diabetes. Backed by prominent institutional investors like OrbiMed and Torrey Pines, the combined entity will possess an extended cash runway through 2027 and face multiple near-term clinical catalysts, making it an attractive high-upside play for biotech investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$4.00 Mean target$5.00 High · most bullish analyst$6.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.5015% The merger with Clywedog faces unexpected regulatory or shareholder delays, or the combined company's upcoming clinical readouts in late 2026 fail to show clear efficacy or present safety concerns. A lack of clinical progress forces the company to seek highly dilutive financing or further restructure its pipeline, severely depressing the stock price. Base CaseCentral scenario $4.0060% The Clywedog merger is completed, and the combined company establishes its new NASDAQ listing under 'CLYD'. Standalone and combined cash reserves successfully fund operations through 2027. Phase 1 MAD data for VTP-1000 and Phase 2a data for CLY-101 meet safety and primary efficacy endpoints, keeping the pipeline on track and supporting steady upward valuation toward consensus analyst targets. Bull CaseUpside scenario $7.0025% The merger with Clywedog closes smoothly, and the combined company successfully delivers positive Phase 2a proof-of-concept data for CLY-101 in diabetes alongside positive Phase 1 MAD data for VTP-1000 in celiac disease during the second half of 2026. Strong clinical validation attracts major pharmaceutical partnerships, non-dilutive funding, or a premium acquisition offer, driving substantial valuation expansion. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |